PE78899A1 - Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE78899A1
PE78899A1 PE1998000466A PE00046698A PE78899A1 PE 78899 A1 PE78899 A1 PE 78899A1 PE 1998000466 A PE1998000466 A PE 1998000466A PE 00046698 A PE00046698 A PE 00046698A PE 78899 A1 PE78899 A1 PE 78899A1
Authority
PE
Peru
Prior art keywords
piridil
etoxi
bencil
diona
thiazolidin
Prior art date
Application number
PE1998000466A
Other languages
English (en)
Spanish (es)
Inventor
Hamish Ross
Robin Price
Jeffrey Roger Granett
Jaikrishna Patel
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE78899A1 publication Critical patent/PE78899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE1998000466A 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona PE78899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
PE78899A1 true PE78899A1 (es) 1999-10-22

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000466A PE78899A1 (es) 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Country Status (29)

Country Link
EP (1) EP0998284A1 (fr)
JP (1) JP2001521553A (fr)
KR (1) KR20010013410A (fr)
CN (3) CN1112926C (fr)
AP (1) AP1214A (fr)
AR (2) AR015120A1 (fr)
AU (1) AU8215098A (fr)
BG (1) BG104048A (fr)
BR (1) BR9810405A (fr)
CA (2) CA2333352A1 (fr)
CO (1) CO4940400A1 (fr)
DZ (1) DZ2510A1 (fr)
EA (1) EA002384B1 (fr)
GB (1) GB9711683D0 (fr)
HU (1) HUP0004070A3 (fr)
ID (1) ID24264A (fr)
IL (1) IL133074A0 (fr)
MX (1) MXPA99011322A (fr)
NO (2) NO995938L (fr)
NZ (2) NZ523725A (fr)
OA (1) OA11306A (fr)
PE (1) PE78899A1 (fr)
PL (1) PL337201A1 (fr)
SK (1) SK164899A3 (fr)
TR (2) TR200002790T2 (fr)
TW (1) TW570797B (fr)
UY (1) UY25032A1 (fr)
WO (1) WO1998055122A1 (fr)
ZA (2) ZA984826B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1903043A1 (fr) 1999-04-23 2008-03-26 SmithKline Beecham P.L.C. Nouveau composé pharmaceutique
UA67844C2 (uk) * 1999-04-23 2004-07-15 Смітклайн Бічам Плс Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (fr) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. Acide 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioique, procédés de préparation et compositions avec le maléate de rosiglitazone
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (fr) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Composés hétécycliques bicycliques utilisés en tant que modulateurs des ror-gamma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (fr) * 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CA2182986A1 (fr) * 1994-02-10 1995-08-17 Smithkline Beecham P.L.C. Utilisation de sensibilisateurs a l'insuline dans le traitement de l'insuffisance renale
EA199800177A1 (ru) * 1995-08-10 1998-10-29 Варнер-Ламберт Компани Способ снижения количества экзогенного инсулина, вводимого пациенту с инсулиннезависимым сахарным диабетом
WO1997018811A1 (fr) * 1995-11-17 1997-05-29 Warner-Lambert Company Procede de traitement de dystrophie myotonique
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
CA2260044A1 (fr) * 1996-07-12 1998-01-22 Stephen Alistair Smith Nouveau traitement contre la resistance a la leptine

Also Published As

Publication number Publication date
WO1998055122A1 (fr) 1998-12-10
AU8215098A (en) 1998-12-21
IL133074A0 (en) 2001-03-19
CA2333352A1 (fr) 1998-12-10
CA2292629A1 (fr) 1998-12-10
AP9901696A0 (en) 1999-12-31
ID24264A (id) 2000-07-13
NO20040738L (no) 2000-02-02
NO995938L (no) 2000-02-02
TW570797B (en) 2004-01-11
NZ513922A (en) 2001-09-28
DZ2510A1 (fr) 2003-01-25
ZA9811572B (en) 1999-07-22
JP2001521553A (ja) 2001-11-06
AR008198A1 (es) 1999-12-29
EA199901116A1 (ru) 2000-06-26
UY25032A1 (es) 1998-11-26
NO995938D0 (no) 1999-12-03
CO4940400A1 (es) 2000-07-24
CN1526391A (zh) 2004-09-08
EP0998284A1 (fr) 2000-05-10
CN1430959A (zh) 2003-07-23
BG104048A (bg) 2000-07-31
PL337201A1 (en) 2000-08-14
CN1259050A (zh) 2000-07-05
CN1112926C (zh) 2003-07-02
ZA984826B (en) 1999-08-03
BR9810405A (pt) 2000-08-29
AP1214A (en) 2003-10-08
EA002384B1 (ru) 2002-04-25
CA2292629C (fr) 2004-01-06
AR015120A1 (es) 2001-04-18
TR199902963T2 (xx) 2000-02-21
SK164899A3 (en) 2000-11-07
HUP0004070A2 (hu) 2002-02-28
MXPA99011322A (es) 2004-12-02
TR200002790T2 (tr) 2001-11-21
NZ523725A (en) 2004-09-24
KR20010013410A (fr) 2001-02-26
HUP0004070A3 (en) 2002-03-28
OA11306A (en) 2003-10-22
GB9711683D0 (en) 1997-08-06

Similar Documents

Publication Publication Date Title
PE78899A1 (es) Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
PE20001036A1 (es) Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso
TR200001880T2 (tr) İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.
PE20000550A1 (es) Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv
AR019636A1 (es) Dispositivo para el acoplamiento de dientes de excavadoras.
MA30598B1 (fr) Composition pharmaceutique contenant un acide tetrahydrofolique.
BRPI0609515A8 (pt) Composto, composição farmacêutica, e, uso de um composto
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
EP1106210A3 (fr) Combinaisons pour le traitement de complications diabétiques, comprenant un inhibiteur de reductase d'aldose et un agents antihypertensif
JO2239B1 (en) Method for preparing benzothophen derivatives
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
ES2188766T3 (es) Composicion farmaceutica que contiene lamotrigina.
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
DE69928500D1 (de) Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetate
ID27649A (id) Proses pembuatan kertas
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten

Legal Events

Date Code Title Description
FC Refusal